SCHEMBL6371206

SCHEMBL6371206

CCc1cc(-c2ccc(CN3CCC(O)C3)o2)c(C)[nH]c1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 6/20 0.39
▸ PIM1 P11309 5/20 0.39
▸ PIM2 Q9P1W9 5/20 0.39
▸ PIM3 Q86V86 3/20 0.39
▸ CSNK2A2 P19784 2/20 0.39
▸ CSNK2B P67870 2/20 0.39
▸ CSNK2A1 P68400 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ LMNA P02545 1/20 0.37
▸ PARP1 P09874 1/20 0.35
▸ CD274 Q9NZQ7 3/20 0.34
▸ PDCD1 Q15116 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PDCD1LG2 Q9BQ51 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2672841 0.99 CDC7 (0.39) CDC7PIM1PIM2PIM3CSNK2A2
SCHEMBL6371224 0.90 CDC7 (0.38) CDC7PIM1PIM2PIM3CSNK2A2
SCHEMBL6372024 0.84 ALDH1A1 (0.41) CYP1A2POLBKMT2AALDH1A1
SCHEMBL6371216 0.82 HTT (0.41) LMNAPOLBKMT2AALDH1A1
SCHEMBL2673527 0.76 ALDH1A1 (0.46) CYP1A2POLBALDH1A1
SCHEMBL6371112 0.74 PIM1 (0.40) PIM1LMNAPARP1POLBKMT2A
SCHEMBL2672706 0.74 CYP2A6 (0.49) CYP1A2ALDH1A1
Hydrochloric Acid SCHEMBL2674369 0.73 PIM1 (0.40) PIM1LMNAPARP1POLBKMT2A
SCHEMBL6372169 0.73 OPRK1 (0.38) CDC7PIM1PIM2LMNAPARP1
SCHEMBL918327 0.72 CDC7 (0.36) CDC7PIM1PIM2PIM3CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 — — EP claimed
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 — — EP disclosed
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-08-09 — — US disclosed
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-08-09 — — US disclosed
US-8173682-B2 Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-05-08 — — US disclosed
US-8173682-B2 Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2012-05-08 — — US disclosed
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2007-02-08 — — US disclosed
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202795-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 CDC7 1271/4885PIM1 2169/4885PIM2 2356/4885
US-20070032489-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) PARP1, PARP2, PARP3 CDC7 1271/4885PIM1 2169/4885PIM2 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback